Syndax Pharmaceuticals (SNDX) TD Cowen 46th Annual Health Care Conference summary

Company overview and recent performance

• Two commercial products in hematology: one for acute AML, one for chronic GVHD, with three approvals in about a year.

• Revuforj achieved $125 million in its first year, setting a new benchmark for AML product launches.

• Niktimvo generated $152 million in 11 months, outperforming previous competitors in chronic GVHD.

• Organization is well-capitalized with $400 million in cash, aiming for profitability with flat operating expenses.

• High formulary coverage and strong infrastructure support further growth and expansion.

Product launches and market dynamics

• Revuforj's launch driven by KMT2A and NPM1 indications, with KMT2A nearing 50% market penetration in its first year.

• NPM1 indication grew from 10% to over 30% of new patient starts after approval.

• Post-transplant maintenance is a key growth driver, with 40-45% of transplant patients returning to therapy.

• Niktimvo is gaining share in third and fourth-line chronic GVHD, with 60-70% patient persistency at 10-11 months.

• Both products are expected to expand into larger markets with new indications and frontline use.

Market opportunity and growth outlook

• Total addressable market for Revuforj in relapsed/refractory AML estimated at over $2 billion, with $750 million for KMT2A and $1.2-1.4 billion for NPM1.

• Frontline AML market could reach $10 billion with longer therapy durations and broader patient access.

• Niktimvo's relapsed/refractory market is about $2 billion, with frontline opportunity exceeding $5 billion.

• Duration of therapy expected to increase from 4-6 months to 6-12 months as more patients return post-transplant.

• Competitive advantage attributed to first-mover status, broad indications, and robust efficacy and safety data.